Dsm-firmenich To Sell ANH Business To CVC Capital Partners For EUR 2.2 Bln; Stock Down

dsm-firmenich agreed to divest its Animal Nutrition & Health (ANH) business to CVC Capital Partners for an enterprise value of about €2.2bn (including up to €0.5bn earnout), while retaining a 20% stake in the split ANH Companies; ANH generated ~€3.5bn annualised net sales in 2025. The company expects to receive ~€1.2bn net proceeds, will launch a €0.5bn share buyback in Q1 and maintain a stable €2.50 ordinary dividend with a progressive outlook; the deal triggers a ~€1.9bn non-cash impairment in 2025 and ~€0.2bn of cash tax/transaction/separation costs in 2026, and is subject to regulatory approvals with completion expected end-2026.

Analysis

Market structure: CVC’s €2.2bn EV purchase (20% retained by DSM‑Firmenich) pushes ANH into private ownership, concentrating animal‑nutrition assets under a PE operator likely to pursue margin improvement and bolt‑on rollups; incumbents in animal feed additives (e.g., Evonik EVK.DE, Elanco ELAN) face a more aggressive, cost‑focused competitor while DSM‑Firmenich (DSFIY / DSFIR.AS) refocuses on higher‑margin consumer nutrition/beauty. The announced €0.5bn share buyback and stable/gradually rising €2.50 dividend create buyback-driven EPS support in the near term (starting Q1) even after a €1.9bn non‑cash impairment hit in 2025. Supply/demand: splitting ANH and a long‑term vitamins supply agreement reduces short‑term disruption risk for human/pet foods but hands volume pricing flexibility to a PE owner — expect tighter commercial discipline and possible price increases in B2B segments over 12–36 months. Cross‑asset: credit metrics should modestly improve when €1.2bn cash is received at close, benefiting corporate bonds and lowering CDS spreads; equity implied volatility should spike around Feb 12 results and again at close/end‑2026, offering option opportunities.

Key Decisions for Investors

• Establish a tactical 2–3% long position in DSM‑Firmenich (DSFIY / DSFIR.AS) ahead of its Feb 12 FY2025 release to capture buyback/dividend visibility; set a 10% stop and a 15–25% target over 6–12 months, trimming into strength if management commits to the €0.5bn repurchase cadence.
• Buy a calendar call spread (long Jan 2027 1× short Jan 2026) on DSFIY to play re‑rating into consumer focus and buyback execution while financing premium with nearer‑term sales; size to 1–2% notional and cap max loss at premium paid.
• Short 1–2% position in Evonik (EVK.DE) or reduce exposure to animal‑nutrition exposed names (e.g., Elanco ELAN by ~25%) to express risk from a PE owner consolidating ANH and compressing raw‑material pass‑throughs over 12–36 months.
• Avoid buying ANH peers’ long‑dated paper; instead, favor short‑dated corporate bonds of animal‑nutrition suppliers into potential margin pressure—sell 6–18 month duration in names with >30% revenue exposure to feed/vitamins.
• Monitor three catalysts before increasing size: (A) Feb 12 results (EPS guidance and buyback timing), (B) regulatory clearance notices and separation timeline through 2026, (C) any revision to the €0.5bn earnout—act within 7–90 day windows around these events.